FDA Accepts Supplemental NDA for FUROSCIX by SCPHARMACEUTICALS
The FDA has accepted a supplemental NDA for FUROSCIX, a formulation of furosemide.
Published: July 29, 2026
Updated: July 29, 2026
Author: Humanexa Intelligence
Therapeutic area: Cardiology / Diuretic
Asset: SCPHARMACEUTICALS
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
SCPHARMACEUTICALS
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's acceptance of the supplemental NDA for FUROSCIX is a significant regulatory milestone that could strengthen SCPHARMACEUTICALS' competitive position in the diuretic market. Portfolio teams need to assess the implications for their existing products and prepare for potential market shifts.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the timeline for FDA review outcomes and any subsequent market launch announcements.
Related companies & assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.